Strong Data For CARsgen’s CAR-T In Late-Line Gastric Cancer

Survival Benefits Demonstrated

 
• By Dexter Jie Yan
  
3D illustration of T cells attacking a cancer cell (CAR-T cell therapy) - Illustration
CARsgen Therapeutics’ satricabtagene autoleucel is world’s first CAR-T cell therapy candidate to deliver positive clinical results in solid tumors. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from Cell Therapies